KCS

CrystalGenomics Inc. is a clinical stage biopharmaceutical company with protein structure based drug discovery and clinical development capabilities, headquartered in Seoul, Korea with a US presence for multi-national clinical management (CG Pharmaceuticals, Inc.) in Emeryville, California and publicly traded on KOSDAQ exchange (Korea). CrystalGenomics is dedicated to the discovery and development of novel pharmaceuticals in areas of infectious disease, cancer, and inflammatory diseases. The company’s capabilities have been validated thru prestigious publications including a cover page on nature for scientific accomplishment (2003), R&D collaborations with prominent pharmaceutical companies including AstraZeneca (2010), and a joint venture deal with ProQuest Investments involving a very early stage asset (2008). The Company’s lead development candidate is a next generation NSAID, CG100649 with a novel mechanism of suppressing COX-2 as well as carbonic anhydrase enzymes for improved cardiovascular, gastrointestinal, and renal safety profiles which is in preparation of Phase 3 study for osteoarthritis. Additionally, its novel HDAC inhibitor, CG200745 for cancer is in Phase 1, and a novel antibiotic candidate, CG400549 for MRSA infection, is in Phase 2a Study in the US.